Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment-free remission in CML

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Key clinical point: Second-line nilotinib led to treatment-free remission in CML patients who achieved sustained molecular response.

Major finding: In total, 58% of patients who switched to nilotinib experienced treatment-free remission at 48 weeks.

Study details: A single-group, open-label phase 2 study.

Disclosures: Novartis Pharmaceuticals funded the study. The researchers reported financial ties to Novartis and other pharmaceutical companies.

Source: Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Read the article.

Citation:

Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

This Week's Must Reads

Monetary support affects select prescribing, Mitchell AP et al. JAMA Intern Med. 2018 Apr 9. doi: 0.1001/jamainternmed.2018.0776

Best TKI options in ALL, Jabbour E et al. Clin Lymphoma Myeloma Leuk. 2018 18(4):257-65

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

Blinatumomab eliminates residual B-cell ALL, Gökbuget N et al. Blood. 2018 Apr 5;131(14):1522-31.

Aryl hydrocarbon receptor antagonist boosts cord blood engraftment, Wagner J et al. 2018 Bone Marrow Transplant Tandem Meetings, Abstract 4.

Must Reads in CML

Treatment-free remission in CML, Mahon FX et al. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1094.

Bosulif Approved to Treat Newly-Diagnosed Ph+ CML, Avillion news release; 2017 Dec 19

Sprycel Approved for Children with Ph+ CML, FDA news release; 2017 Nov 9

Be Sure to Consider This When Selecting TKIs, Clin Lymphoma Myeloma Leuk; ePub 2017 Jun 16; Coutinho, et al

FDA Approves Iclusig for Certain Types of CML, ALL, Ariad news release; 2016 Nov 29